TRCT
ABOS icon

Tower Research Capital (TRC)’s Acumen Pharmaceuticals ABOS Stock Holding History

Tower Research Capital (TRC)’s Portfolio ABOS Stock Details ABOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$278 Sell
118
-4,339
-97% -$11.1K ﹤0.01% 4928
2025
Q4 		$9.4K Buy
+4,457
New +$8.84K ﹤0.01% 3900
2025
Q3 		– Sell
-3,631
Closed -$4.21K – 5191
2025
Q2 		$4.21K Sell
3,631
-4,810
-57% -$5.17K ﹤0.01% 4361
2025
Q1 		$9.29K Sell
8,441
-12,183
-59% -$17.4K ﹤0.01% 3797
2024
Q4 		$35.5K Buy
20,624
+16,714
+427% +$40.2K ﹤0.01% 2790
2024
Q3 		$9.7K Sell
3,910
-22,578
-85% -$61.2K ﹤0.01% 3844
2024
Q2 		$64.1K Buy
26,488
+25,078
+1,779% +$79.8K ﹤0.01% 2909
2024
Q1 		$5.71K Sell
1,410
-27,679
-95% -$104K ﹤0.01% 4503
2023
Q4 		$112K Buy
29,089
+26,961
+1,267% +$80K ﹤0.01% 2566
2023
Q3 		$8.83K Sell
2,128
-1,447
-40% -$8.94K ﹤0.01% 4297
2023
Q2 		$17.2K Buy
3,575
+553
+18% +$2.65K ﹤0.01% 3515
2023
Q1 		$12K Sell
3,022
-250
-8% -$1.31K ﹤0.01% 4042
2022
Q4 		$18K Sell
3,272
-4,845
-60% -$32.6K ﹤0.01% 3196
2022
Q3 		$81K Buy
8,117
+4,232
+109% +$24.3K ﹤0.01% 2740
2022
Q2 		$18K Buy
3,885
+1,330
+52% +$5K ﹤0.01% 3880
2022
Q1 		$10K Sell
2,555
-3,968
-61% -$21.6K ﹤0.01% 4266
2021
Q4 		$44K Buy
6,523
+5,828
+839% +$64.1K ﹤0.01% 2852
2021
Q3 		$10K Buy
+695
New +$11.6K ﹤0.01% 4299

Other funds holding ABOS

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
KIA
Knollwood Investment Advisory Hunt Valley, Maryland $992M AUM 28.95% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

Tower Research Capital (TRC)'s ABOS Position: Q1 2026 in Review

Tower Research Capital (TRC) reduced its Acumen Pharmaceuticals (ABOS) stake by 97% in Q1 2026, selling an estimated $11.1K and leaving 118 shares worth $278. The position accounts for ﹤0.01% of the portfolio, ranked #4928.

Tower Research Capital (TRC) first reported a position in ABOS in Q3 2021 and has held it in 18 quarters since. The position peaked at $112K in Q4 2023. 84 funds tracked by Wall St. Rank hold ABOS as of Q1 2026.

  • Tower Research Capital (TRC) held 118 shares of Acumen Pharmaceuticals worth $278 as of Q1 2026.
  • Tower Research Capital (TRC) sold 4,339 Acumen Pharmaceuticals shares in Q1 2026, an estimated $11.1K.
  • Acumen Pharmaceuticals made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #4928 holding.
  • Tower Research Capital (TRC) first reported a position in Acumen Pharmaceuticals in Q3 2021 and has held it in 18 quarters since.
  • Tower Research Capital (TRC)'s Acumen Pharmaceuticals position peaked at $112K in Q4 2023.
  • 84 funds tracked by Wall St. Rank held Acumen Pharmaceuticals as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.